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Human CARD9 deficiency is an autosomal recessive primary immunodeficiency disorder
caused by biallelic mutations in the gene CARD9, which encodes a signaling protein
that is found downstream of many C-type lectin receptors (CLRs). CLRs encompass
a large family of innate recognition receptors, expressed predominantly by myeloid
and epithelial cells, which bind fungal carbohydrates and initiate antifungal immune
responses. Accordingly, human CARD9 deficiency is associated with the spontaneous
development of persistent and severe fungal infections that primarily localize to the
skin and subcutaneous tissue, mucosal surfaces and/or central nervous system (CNS).
In the last 3 years, more than 15 missense and nonsense CARD9 mutations have
been reported which associate with the development of a wide spectrum of fungal
infections caused by a variety of fungal organisms. The mechanisms by which CARD9
provides organ-specific protection against these fungal infections are now emerging. In
this review, we summarize recent immunological and clinical advances that have provided
significant mechanistic insights into the pathogenesis of human CARD9 deficiency. We
also discuss how genetic mutations in CARD9-coupled receptors (Dectin-1, Dectin-2)
and CARD9-binding partners (MALT1, BCL10) affect human antifungal immunity relative
to CARD9 deficiency, and we highlight major understudied research questions which
merit future investigation.
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The last 3 years have seen an increasing number of reports of patients with overwhelming fungal
disease attributed to a genetic mutation in the gene CARD9 (Caspase Recruitment Domain Family,
member 9). Human CARD9 deficiency was first described in 2009 in a consanguineous family
aﬄicted with mucosal and lethal systemic infections caused by Candida species, (Glocker et al.,
2009), which are common human commensal yeasts (Lionakis and Netea, 2013). Since then,
more than 15 other CARD9 mutations have been identified in 46 patients, that uniquely associate
with mucosal and/or systemic infections caused by specific fungal phyla (Drewniak et al., 2013;
Lanternier et al., 2013; Gavino et al., 2014; Lanternier et al., 2014; Wang et al., 2014; Drummond
et al., 2015; Gavino et al., 2015; Grumach et al., 2015; Herbst et al., 2015; Jachiet et al., 2015;
Lanternier et al., 2015; Liang et al., 2015; Celmeli et al., 2016; Yan et al., 2016). These reports
unequivocally demonstrate the critical dependence on CARD9 in human antifungal immunity.
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Fungi are recognized by the innate immune system via pattern
recognition receptors (PRRs) belonging to several different
classes, including the C-type lectin receptors (CLRs), Toll-
like receptors (TLRs), and the intracellular nucleotide-binding
oligomerization domain-like receptors (NLRs), which are
predominantly expressed by myeloid cells including neutrophils,
monocytes, macrophages, and dendritic cells (Hardison and
Brown, 2012). Although all of these receptor families are involved
in innate antifungal recognition, only mutations in the CLR
pathway have thus far been associated with the spontaneous
development of fungal infections in humans.
Many members of the CLR superfamily bind fungal
carbohydrates and initiate complex intracellular signaling
pathways to mediate cellular functions, such as fungal killing
and production of pro-inflammatory cytokines (Lionakis and
Netea, 2013). Several CLRs utilize a common signaling pathway
involving the kinase Syk and the signaling adaptor, CARD9
(Gross et al., 2006; Drummond et al., 2011). Thus, CARD9 is
centrally positioned downstream of many CLRs and is critical for
their function.
In this review, we highlight recent novel immunological
insights into the pathogenesis of human CARD9 deficiency and
summarize the different human CARD9 mutations described
to date along with their clinical and functional characteristics
(Table 1). In addition, we discuss how genetic mutations in
the CARD9-coupled receptors (e.g., Dectin-1, Dectin-2) and
molecules that form signaling complexes with CARD9 (e.g.,
MALT1, BCL10) affect human antifungal immunity (Table 2),
while highlighting major understudied areas that merit future
investigation.
HUMAN CARD9 DEFICIENCY UNIQUELY
PREDISPOSES TO MUCOSAL AND
SYSTEMIC FUNGAL DISEASES
The vast majority of inborn errors in immunity that predispose
to fungal disease typically also lead to the development of non-
fungal infections. Furthermore, these disorders usually segregate
cleanly betweenmucosal or systemic fungal disease susceptibility,
whereas CARD9 deficiency predisposes to both mucosal and
systemic fungal disease. The only other inherited conditions
that match the combined susceptibility to mucosal and systemic
fungal infections seen in CARD9 deficiency are gain-of-function
STAT1 mutations and autosomal-dominant STAT3 mutations;
however, these mutations also result in bacterial, mycobacterial
and/or viral infections (reviewed in detail here Lionakis et al.,
2014). In contrast, CARD9 mutations in humans have thus
far only been associated with fungal infections (Table 2),
although Card9−/− mice have been reported to be susceptible to
intracellular bacterial infections (Hsu et al., 2007; Dorhoi et al.,
2010) in addition to their susceptibility to fungal disease.
In mouse models of fungal challenge, Card9 genetic deletion
abolishes the ability to control systemic Candida albicans
infections, with 100% mortality observed as early as 72 h
post-infection (Gross et al., 2006; Drummond et al., 2015).
Similar results were recently obtained with Candida tropicalis,
an emerging non-albicans Candida species, where fungal growth
was found to be uncontrolled in the kidney, spleen, liver, and
brain (Whibley et al., 2015). Card9−/− animals were also found
to be mildly susceptible to mucosal candidiasis; however, this
was only evident during secondary infection suggesting that
the dependence on Card9 lies within the adaptive immune
compartment for this particular disease (Bishu et al., 2014). The
difference between human and mouse susceptibility to mucosal
fungal disease in the setting of CARD9-deficiency may be a
reflection of the fact that, as opposed to humans, Candida is
not a commensal organism in mice (Table 2). Susceptibility
to pulmonary disease caused by the inhaled mold Aspergillus
fumigatus is modestly enhanced in Card9−/− animals, but
only when these animals are challenged with an overwhelming
number of conidia (8 × 107; Jhingran et al., 2012), whereas
challenge with the still supra-physiologic inoculum, 3 × 107
conidia, does not confer heightened susceptibility in Card9−/−
mice (Jhingran et al., 2015). These mouse data are in line with the
lack of an association between pulmonary mold infections and
human CARD9-deficiency to date. More work will be required in
mice to determine the role of Card9 in host defense against non-
Candida, non-Aspergillus fungal pathogens that have been shown
to cause disease in CARD9-deficient patients (Table 1).
Sixteen human CARD9 mutations have now been identified
and characterized in patients originating from the USA, Canada,
Europe, Middle East, South America, and China (Glocker et al.,
2009; Drewniak et al., 2013; Lanternier et al., 2013; Gavino et al.,
2014; Lanternier et al., 2014; Wang et al., 2014; Drummond
et al., 2015; Grumach et al., 2015; Herbst et al., 2015; Jachiet
et al., 2015; Lanternier et al., 2015; Yan et al., 2016). These
mutations are found in the promoter region and the coiled-coil
and CARD protein domains of CARD9, and both nonsense and
missense mutations have been described (Table 1). Consistent
with an autosomal recessive mode of inheritance, 80% of the
reported patients were from consanguineous families; 89% were
homozygous for the same allele, whereas 11% were compound
heterozygous for different alleles. These mutations have variable
penetrance, age of onset and effects, such that CARD9-deficiency
manifests with multiple diseases caused by a variety of fungal
organisms (Table 1). Based on the observed clinical variability
thus far, the manifestations of human CARD9 deficiency can be
broadly divided into three disease syndromes.
The first syndrome associated with CARD9 deficiency affects
the skin and subcutaneous tissues, and patients in this category
present with dramatic persistent fungal infections of the skin,
nails and/or scalp (Lanternier et al., 2013;Wang et al., 2014), with
occasional contiguous dissemination to the subcutaneous layers,
lymph nodes and bone (Lanternier et al., 2013). The etiological
agents for these infections so far described include Trichophyton
species (causing deep dermatophytosis; Lanternier et al., 2013),
Phialophora verrucosa (an agent of phaeohyphomycosis; Wang
et al., 2014), and one intriguing case of phaeohyphomycosis
caused by the plant pathogen Corynespora cassiicola (Yan et al.,
2016). The CARD9-dependent functions that provide organ-
specific protection in the skin against dermatophytes and agents
of phaehyphomycosis are currently not well defined. In mouse
models of cutaneous C. albicans infection, it has been shown
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TABLE 2 | Summary of infection susceptibilities to fungal and non-fungal pathogens in humans and mice deficient (or expressing non-functional variants)
in the indicated CARD9-coupled receptors and associated signaling molecules.
Human Mouse Selected References
Associated Susceptibility Associated Susceptibility
fungal infections to non-fungal pathogens fungal infections to non-fungal pathogens
CARD9-COUPLED RECEPTORS
Dectin-1 Candidiasis (mucosal,
VVC), dermatophytosis
NR Systemic candidiasis,
pulmonary aspergillosis,
pulmonary pneumocystis
pulmonary coccidioidomycosis
NR Drummond et al., 2011
Dectin-2 NR NR Systemic candidiasis Streptococcal pneumonia Akahori et al., 2016
Dectin-3 NR NR Systemic candidiasis Mycobacterial disease Zhu et al., 2013; Wilson
et al., 2015
Mincle NR NR Systemic candidiasis NR Hardison and Brown, 2012
SIGNALING MOLECULES
CARD9 See Table 1 NR Systemic candidiasis,
pulmonary aspergillosis
Listeria monocytogenes,
mycobacterial disease
Gross et al., 2006; Hsu
et al., 2007; Dorhoi et al.,
2010; Jhingran et al., 2012
BCL10 CMC Bacterial gastrointestinal
infections (Campylobacter,
Clostridium difficile), viral
gastrointestinal and
pulmonary infections
(adenovirus, influenza)
NR Viral infections (LCMV, VSV) Ruland et al., 2001; Torres
et al., 2014; de Diego et al.,
2015
MALT1 CMC Bacterial pneumonia, CMV NR NR Jabara et al., 2013; de
Diego et al., 2015
Trim62 NR NR Systemic candidiasis NR Cao et al., 2015
Rubicon NR NR Systemic candidiasis* Influenza A* Yang et al., 2012
*These results were obtained using viral vectors to either increase or decrease Rubicon expression in vivo. Rubicon expression adversely affected immunity to these pathogens, whereas
viruses carrying silencing RNA enhanced protection. NR, not reported; CMC, chronic mucocutaneous candidiasis; VVC, vulvovaginal candidiasis; LCMV, lymphocytic choriomeningitis
virus; VSV, vesicular stomatitis virus; CMV, cytomegalovirus.
that IL-17A and IL-23 signaling are critical for antifungal host
defense in the skin (Kagami et al., 2010), and that induction of
Th17 immunity is dependent on the CARD9-coupled receptor
Dectin-1 expressed by Langerhans cells (Kashem et al., 2015),
a population of dendritic cells resident in the epidermal layers
of the skin. Both of these studies used C. albicans to initiate
infection and did not investigate the dependence on Card9 for
these activities. It therefore remains to be explored whether
IL-17-dependent mechanisms of clearance require CARD9 for
antifungal defense in the skin, and how important these
mechanisms are for clearance of dermatophytes and agents
of phaeohyphomycosis, where innate killing mechanisms of
neutrophils and macrophages appear important (de Sousa et al.,
2015; Liang et al., 2015).
The second predominant manifestation of human CARD9-
deficiency is systemic fungal disease, which primarilymanifests as
fungal meningoencephalitis caused by Candida species (Gavino
et al., 2014; Drummond et al., 2015). Some of these patients
have also developed accompanying bone infection of the vertebra
(Gavino et al., 2014; Drummond et al., 2015). Less often,
CARD9-deficient patients develop phaeohyphomycosis caused
by Exophiala species that targets the central nervous system
(CNS) and/or other deep tissues including the liver, lung, and
bone (Lanternier et al., 2014). Strikingly, Candida infections
involving the kidney, liver or spleen, the organs typically affected
in patients with iatrogenic immunosuppression (Lionakis, 2014),
have not been reported in CARD9-deficient patients. Similarly,
pulmonary infections by ubiquitous inhaled molds, or infections
by Cryptococcus neoformans, Cryptococcus gattii, Pneumocystis
jirovecii, and the endemic dimorphic fungi (i.e., Histoplasma
capsulatum, Coccidioides immitis, or Blastomyces dermatitidis)
have also not been reported thus far in CARD9-deficient patients.
Collectively, the tropism of organ-specific systemic fungal disease
in CARD9 deficiency implies that CARD9 has fungal- and organ-
specific innate immune effects, which we currently only partially
understand.
In addition to cutaneous/subcutaneous and CNS fungal
disease, many CARD9-deficient patients are also susceptible to
persistent and recurrent infections of the mucosal surfaces by
Candida species, collectively termed chronic mucocutaneous
candidiasis (CMC). CMC can develop as a single entity
or in association with the aforementioned systemic or
cutaneous/subcutaneous fungal diseases, and the mouth,
gut and vagina have all been reportedly affected in CARD9-
deficient patients (Table 1). When CMC and systemic fungal
disease occur in the same individual, it appears that CMC starts
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at an earlier age and often pre-dating the development of the
more serious fungal diseases affecting the brain (Drummond
et al., 2015; Grumach et al., 2015; Lanternier et al., 2015). CARD9
deficiency is the only reported human genetic disorder where
mucosal and systemic Candida disease occur together in the
absence of other non-fungal infections (Lionakis et al., 2014).
This is a rare event for patients to develop both mucosal and
systemic Candida infections, since each disease has differing
requirements for immune protection. Specifically, mucosal
candidiasis control requires IL-17 signaling via Th17 cells, γδ
T-cells and innate lymphoid cell populations (Conti et al., 2009;
Gladiator et al., 2013; Conti et al., 2014), whereas systemic
defense depends heavily on the accumulation and effector
function of neutrophils and mononuclear phagocytes (Brown,
2011; Lionakis and Netea, 2013; Lionakis, 2014). Therefore,
CARD9 deficiency gives rise to detrimental effects in both
lymphoid and myeloid cell accumulation and/or function.
IMPAIRED INDUCTION OF IL-17
RESPONSES MAY ACCOUNT FOR
MUCOSAL FUNGAL DISEASE IN
CARD9-DEFICIENT HUMANS
As CARD9-deficiency is associated with a spectrum of fungal
diseases, this could indicate at the varying requirements for
CARD9-dependent functions at different anatomical sites, since
antifungal immune responses vary drastically between organs
(Lionakis et al., 2011). As mentioned above, Th17 responses
are required for protection against mucosal candidiasis in both
mice and humans, whereas there is far less dependence on
these responses for systemic anti-Candida defense (Conti and
Gaffen, 2015). The critical role of CARD9 in the induction of IL-
17 responses (LeibundGut-Landmann et al., 2007; Bishu et al.,
2014) may account for CMC susceptibility of affected patients.
Indeed, the majority of CARD9 mutations are associated with
a reduced number of circulating Th17 cells (Table 1). However,
approximately half of the reported CARD9 missense mutations
have no impact on the percent of peripheral blood Th17 cells
following stimulation with PMA/ionomycin (Table 1). Thus, the
role of CARD9 in human Th17 immunity and defense against
CMC still remains unclear. Further work will be needed to
decipher how human CARD9 deficiency affects the pathways
governing Th17 differentiation and function, and how CARD9
mutations that do not affect peripheral blood Th17 cell numbers
can still result in the development of CMC.
CARD9 IS REQUIRED FOR NEUTROPHIL
RECRUITMENT TO THE
FUNGAL-INFECTED CNS
Our group’s research recently uncovered novel insight into how
human CARD9-deficiency may predispose to fungal infection
of the CNS (Drummond et al., 2015). Prior to this work,
the susceptibility to CNS fungal disease was thought to be
the result of a selective defect in killing unopsonized C.
albicans yeasts by CARD9-deficient neutrophils (Drewniak et al.,
2013; Drummond et al., 2015). Since opsonization is naturally
low in the CNS, this killing defect has been thought to be
clinically relevant in this tissue thus potentially accounting
for localized organ-specific disease. Neutrophils are critical
for antifungal host defense in mice and humans (Lionakis
and Netea, 2013), and an intrinsic functional defect in these
cells is a plausible explanation for the susceptibility to fungal
CNS disease in CARD9-deficient patients. However, C. albicans
pseudohyphae, not yeast, is the predominant fungal morphology
observed in infected CNS tissue of mice and humans (Lionakis
et al., 2011; Drummond et al., 2015), and hyphal killing by
CARD9-deficient human neutrophils appears intact (Drewniak
et al., 2013; Drummond et al., 2015). Importantly, we found
that neutrophils are not recruited to the fungal-infected CNS
in a CARD9-deficient patient or infected Card9−/− animals
(Drummond et al., 2015). In line with our findings, other
groups have also reported a lack of neutrophil accumulation in
the Candida-infected CSF of CARD9-deficient patients; instead,
large numbers of lymphocytes and eosinophils comprise the
cellular inflammatory reaction in these patients (Drewniak et al.,
2013; Lanternier et al., 2015; Celmeli et al., 2016). This is in
stark contrast to patients with Candida meningoencephalitis
who have intact CARD9 signaling, where cells recruited to the
infected CSF are predominantly neutrophils (Drummond et al.,
2015). Therefore, although the selective neutrophil killing defect
against unopsonized Candida yeasts may contribute toward the
development of CNS fungal disease in CARD9-deficient patients,
the major contributor toward the CNS infection susceptibility of
CARD9-deficient patients appears to be the lack of neutrophils
in the infected CNS, thus creating a condition of “CNS-specific
neutropenia.”
We investigated the underlying mechanisms for the CNS-
specific neutropenia observed in our CARD9-deficient patient
and Card9−/− animals. Impaired neutrophil accumulation in the
Candida-infected CNS was not the result of defective neutrophil
production in the bone marrow, neutrophil egress into the
blood, neutrophil survival or neutrophil-intrinsic chemotaxis
(Drummond et al., 2015). Instead, we found that CARD9
deficiency confers a lack of CXC-chemokine induction in
the CNS during fungal infection, in both mice and humans
(Drummond et al., 2015). Using mouse models, we found that
CXC-chemokines were induced in a proportional manner to
brain fungal burden, and this relationship was lost in the absence
of Card9 (Drummond et al., 2015). We showed that this defect
is specific to the CNS, since CXC-chemokine production and
neutrophil recruitment were affected in a significantly lesser
extent in the kidney of infected Card9−/− mice, similar to recent
findings using C. tropicalis (Whibley et al., 2015). Furthermore,
we also showed that this defect was specific to fungal infection,
as neutrophil recruitment was also unaffected following bacterial
brain infection (Drummond et al., 2015), in agreement to the
lack of susceptibility to bacterial meningoencephalitis in CARD9-
deficient patients. Future work will be required to define the
Card9-dependent cellular sources of neutrophil-targeted CXC-
chemokines that are required for neutrophil recruitment to the
CNS during fungal invasion, as well as the CARD9-coupled
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receptors critical for this effector cell accumulation. Of interest,
Dectin-1 has been shown to promote neutrophil recruitment in
the C. albicans-infected mouse peritoneum (Taylor et al., 2007),
but its role in neutrophil recruitment in the fungal-infected CNS
has not yet been explored.
Consistent with a role of CARD9 in neutrophil accumulation
during fungal disease, the Hohl group recently characterized
a neutrophil recruitment defect to the A. fumigatus-infected
lung in Card9−/− mice, which was also linked to poor CXC-
chemokine production in the lung (Jhingran et al., 2015).
However, in that model, Card9 was only partially required in
the later stages of infection for neutrophil accumulation in the
infected lung. Instead, neutrophil recruitment in the early phase
was controlled by the TLR/IL-1R signaling adaptor, MyD88,
which was required for chemokine induction by epithelial
cells (Jhingran et al., 2015). Thus, the collective dependence
on Card9 for neutrophil recruitment during pulmonary mold
infections appears relatively mild compared to the universal
reliance required for neutrophil accumulation and protection
against Candida infection in the CNS (Gross et al., 2006;
Drummond et al., 2015; Whibley et al., 2015). This dichotomy
observed in mice between the Card9-dependence for protection
against molds and yeasts may help explain why human CARD9
deficiency does not appear to associate with pulmonary fungal
infections, despite the continuous environmental exposure to
fungal spores. In order to clarify the fungal- and organ-specific
functions of CARD9, future studies will be needed to examine
the mechanistic role of CARD9 on other myeloid cells, besides
neutrophils, such as monocytes, resident macrophages, dendritic
cells, andmyeloid-derived suppressor cells (Rieber et al., 2015), as
well as resident epithelial and stromal cells in mediating systemic
antifungal host defense.
IMMUNE-BASED ADJUNCT TREATMENTS
MAY IMPROVE THE OUTCOME OF
CARD9-DEFICIENT PATIENTS WITH
CANDIDA MENINGOENCEPHALITIS
Immune-based strategies have recently been reported to be an
effective adjunct treatment for fungal meningoencephalitis in
CARD9-deficient patients (Gavino et al., 2014, 2015; Celmeli
et al., 2016), as long-term antifungal usage does not always
lead to clinical remission, especially when treatment is not
aggressive early on (Drummond et al., 2015). For instance,
Gavino et al. showed that exogenous treatment with granulocyte-
macrophage colony stimulating factor (GM-CSF) successfully led
to clinical remission in a cohort of French-Canadian patients
with Candida CNS infection, carrying the p.Y91H allele (Gavino
et al., 2014, 2015). More recently, this work was mirrored by
a second group using the related colony stimulating factor, G-
CSF, administration of which resulted in clinical improvement
in a Turkish patient with the p.Q295X mutation who had
uncontrolled CandidaCNS infection (Celmeli et al., 2016). Long-
term GM-CSF treatment appeared necessary in the French-
Canadian patients as its discontinuation led to clinical relapse,
whereas short-term G-CSF treatment appeared adequate as its
discontinuation did not result in infection relapse (Gavino et al.,
2014, 2015; Celmeli et al., 2016).
At the mechanistic level, the Y91H mutation was shown to
cause a defect in the formation of a CARD9-Ras protein-specific
guanine nucleotide releasing factor 1 (Ras-GRF1) complex,
necessary for downstream NF-κB and ERK signaling, which
subsequently led to defective GM-CSF production in response
to fungal ligands (Gavino et al., 2015). Impaired ERK activation
via altered Card9 association with Ras-GRF1 and H-Ras was
confirmed in Card9−/− mice (Jia et al., 2014). Presumably,
this GM-CSF specific defect may be amenable to correction by
exogenous GM-CSF administration in these patients. In the study
by the Grimbacher group, G-CSF treatment was shown to correct
defective IL-17 production fromCARD9-deficient cells, although
not to the same levels as CARD9+ cells donated by a healthy
volunteer (Celmeli et al., 2016). Both GM-CSF and G-CSF have
pleiotropic effects on the immune system, and could therefore
have potentially rescued CNS infection via boosting neutrophil
recruitment to the site of infection and/or enhancing myeloid
cell effector function, or other as yet unknown mechanisms
may be involved. As these parameters were not examined
in these studies, it is unclear whether GM-CSF/G-CSF could
bypass multiple immune defects associated with human CARD9
deficiency, or if these success stories rely on correcting specific
defects caused by the CARD9 mutation identified in these
particular patients. Additional work testing the efficacy of GM-
CSF/G-CSF in other CARD9-deficient patients with different
mutations and other clinical manifestations beyond Candida
CNS infection, corroborated by similar studies in Card9−/−
mouse models of fungal infections, will be required to determine
the general applicability and the accompanying mechanisms of
these treatments in human CARD9-deficiency.
CLR MUTATIONS DO NOT RESULT IN
DEVELOPMENT OF SYSTEMIC FUNGAL
INFECTIONS IN HUMANS
After ligand binding, CLRs initiate intracellular signaling either
directly via their intracellular tails (e.g., Dectin-1) or indirectly via
association with a signaling adaptor such as FcRγ (e.g., Dectin-
2, Mincle; Drummond et al., 2011). In the Syk/CARD9 pathway,
tyrosine residues in the signaling motif of the CLR tail or adaptor
become phosphorylated by SHP-2 leading to recruitment and
activation of Syk kinase (Deng et al., 2015). Downstream of Syk,
CARD9 forms a signaling complex with BCL10 and MALT1
which provides a scaffold for further signaling events such as NF-
κB activation and the formation and activation of inflammasomes
(Lionakis and Netea, 2013). The formation and regulation of
the CARD9-BCL10-MALT1 (CBM) signaling complex is only
partially understood, however recent reports have identified
CARD9 binding partners that inhibit or activate CLR-CARD9
signaling. For example, TRIM62 is a ubiquitin ligase that
activates CARD9 and thus positively regulates the CLR-CARD9
pathway (Cao et al., 2015). Accordingly, Trim62−/− mice were
recently found to be more susceptible to systemic candidiasis,
with increased tissue fungal burdens and accelerated mortality
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(Cao et al., 2015), although this increase was modest relative
to that seen in Card9−/− animals that develop overwhelming
rapidly-lethal disease (Gross et al., 2006; Drummond et al., 2015).
In contrast, the protein Rubicon was shown to be a negative
regulator of CARD9 signaling, acting to dissemble the CBM
complex and interrupt downstream cytokine production (Yang
et al., 2012). For both of these molecules, as well as other
yet unknown CARD9 signaling partners, their role in human
antifungal immunity remains to be determined (Table 2).
Despite sharing the CARD9 intracellular signaling pathway,
many CLRs exhibit independent functions (reviewed extensively
elsewhere Hardison and Brown, 2012) and form complex
cross-talk relationships that can either be synergistic (Hadebe
et al., 2015) or modulatory (Gringhuis et al., 2011). Although
individual CLRs perform many critical functions, mutations
that disrupt their expression do not lead to development of
spontaneous invasive fungal disease, but are instead associated
with mucosal infections (Table 2). For example, the best-
studied human CLR mutation is p.Y238X in the CLEC7A gene,
which encodes Dectin-1. Dectin-1 is the β-glucan receptor
(Brown, 2006), predominantly expressed by myeloid cells, and is
required for many antifungal activities including fungal killing,
phagocytosis, cytokine production, inflammasome activation,
and CD4+ T-cell survival and function (Drummond and
Brown, 2011; Gringhuis et al., 2012; Drummond et al., 2016).
The Y238X polymorphism causes poor expression of Dectin-1
and defective pro-inflammatory cytokine production following
fungal restimulation (Ferwerda et al., 2009). A family of patients
with this mutation was reported to suffer from frequent bouts
of vulvovaginal candidiasis and onychomycosis (Ferwerda et al.,
2009). In line with this, IL-17 responses were found to be
defective in Y238X cells restimulated with C. albicans yeasts (van
de Veerdonk et al., 2009), and thus disruption of this protective
response could be responsible for the association between Y238X
and mucosal fungal infections described in the above family.
However, the precise role of the Y238X polymorphism in
promoting mucosal fungal disease deserves further investigation,
since this polymorphism has a high prevalence in several human
populations (Ferwerda et al., 2009), yet it is unclear to what extent
carriers of Y238X suffer from such infections. At the population
level, patients carrying the Y238X polymorphism were shown
to be more likely to have oral and gastrointestinal Candida
colonization (Plantinga et al., 2009), and were at greater risk
for developing invasive mold infections following hematopoietic
stem cell transplantation (Cunha et al., 2010), at odds with
the absence of pulmonary fungal infections in CARD9-deficient
patients. At the mechanistic level, the Y238X polymorphism has
no effect on phagocytosis and fungal killing by neutrophils in
vitro, which may account for why these patients do not develop
systemic disease. However, many CARD9 mutations also do not
affect phagocytosis and have only minor effects on fungal killing
(Drewniak et al., 2013; Drummond et al., 2015; Liang et al.,
2015), thus there are likely other complex functions dependent
on CARD9 and independent of Dectin-1 which we have yet to
discover, that are critical for systemic defense.
Other CLR polymorphisms that have been associated with
fungal disease in humans include the Dectin-1 polymorphism
rs2078178 and the Dectin-2 polymorphism rs11045418. The
Dectin-1 variant was found to associate with medically refractory
ulcerative colitis, through an as yet unclear mechanism whereby
the Dectin-1 variants aggravate existing inflammatory bowel
disorders. The authors used mouse models to demonstrate that
C. tropicalis was responsible for worsening colitis in Clec7a−/−
animals, indicative of the involvement of fungi and defective
antifungal immunity in this model (Iliev et al., 2012). Dectin-2 is
another CLR that binds α-mannans and has a similar expression
profile to Dectin-1 (Kerscher et al., 2013), and has been shown
to be particularly important for initiation of antifungal Th17
responses (Saijo et al., 2010; Gringhuis et al., 2011). Recently, a
Dectin-2 polymorphism was found to associate with pulmonary
cryptococcosis, but not with cryptococcal meningitis, in Chinese
patients (Hu et al., 2015). The basis for this association remains
unclear, since Dectin-2-deficient mice are not more susceptible to
pulmonary cryptococcosis (Nakamura et al., 2015) and detailed
studies into the functional consequences of human Dectin-2
polymorphisms are currently lacking. Identification of other
human mutations in CLRs is still in its infancy (Table 2), as
exemplified by the recent characterization of novel CLRs (e.g.,
Dectin-3, Mincle) and thus the full scope and spectrum of CLR-
dependent antifungal immune functions is not yet well defined.
More work is therefore required to comprehensively analyze
the CLR-specific roles in immune responses to various fungal
pathogens.
DEFICIENCIES IN THE CARD9 PARTNERS
MALT1 AND BCL10 HAVE BROAD
EFFECTS ON IMMUNITY
While human CARD9 deficiency is uniquely associated with
fungal disease, human mutations in its partners BCL10 and
MALT1 have wider consequences for the immune system
(reviewed extensively here de Diego et al., 2015, and see Table 2).
MALT1 is required for NF-κB activation and is found
downstream of many immune receptors, including antigen-
specific T- and B-cell receptors, the CLRs, and some G-protein
coupled receptors (de Diego et al., 2015). Recent reports of
patients with MALT1 missense mutations demonstrated that
disruption of MALT1 function has far-reaching consequences
for innate and adaptive immunity resulting in combined
immunodeficiency. These patients suffered from a variety of
infectious and growth disorders, including bacterial pulmonary
infections, CMC, persistent cytomegalovirus infection, and
inflammatory defects in the gut (Jabara et al., 2013; McKinnon
et al., 2014; Punwani et al., 2015). Functionally, MALT1-
deficiency conferred an inability to degrade IκBα and defects in
T-cell derived IL-2 production (Jabara et al., 2013; McKinnon
et al., 2014; Punwani et al., 2015), in line with earlier work
describing the immune defects of Malt1−/− mice (de Diego
et al., 2015). The effects of human MALT1 deficiency on
antifungal immunity have not been studied in detail. However,
Gringhuis and colleagues showed that MALT1 was required for
production of Th17-polarizing cytokines from human dendritic
cells, through a pathway involving Dectin-2 and the NF-κB
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subunit c-Rel (Gringhuis et al., 2011). Thus, the correlation
between human MALT1 deficiency and CMC could be related to
the critical role for Th17 cells in protecting mucous membranes
fromCandida infection, although this has yet to be fully explored.
BCL10, like MALT1, is involved in many immune signaling
pathways and thus BCL10 deficiency also has broad effects
on the hematopoietic and non-hematopoietic immune system.
A young child with complete BCL10 deficiency was recently
described, who died at 3 years of age following multiple viral
infections, CMC, colitis, and gastrointestinal infections (Torres
et al., 2014). Interestingly, macrophages and dendritic cells from
this patient had normal TLR and Dectin-1 mediated responses,
as measured by pro-inflammatory cytokine production following
restimulation with specific ligands. Instead, most of the immune
defects in this patient mapped to the adaptive immune system,
where generation of memory B- and T-cells was severely
compromised (Torres et al., 2014), in line with findings using
Bcl10−/− animals (Ruland et al., 2001). The study of more
patients with MALT1 and BCL10 mutations will be required to
define the full spectrum of susceptibility to mucosal and systemic
fungal disease. In addition, work in mice will be critical to
determine the mechanisms by which Malt1 and Bcl10 promote
mucosal host defense and whether they mediate CNS-specific
protective immunity, as does Card9.
CONCLUDING REMARKS
Systemic fungal infections continue to represent a significant
unmet medical problem associated with high mortality,
making the development of vaccines and novel immune-
based treatments highly desirable in order to improve patient
outcomes. Deciphering the cellular and molecular immune
functions that promote effective antifungal immunity will help
us achieve these goals and improve current clinical approaches.
Human primary immunodeficiency disorders that predispose
to fungal infections give us crucial clues as to which molecules
are important for antifungal host defense. CARD9 is a critical
antifungal molecule yet there remain significant gaps in our
understanding, including the organ-specific functions operating
in the skin, mucosal surfaces, and deep tissues, why CARD9-
deficiency doesn’t predispose to more infections by other fungal
organisms, and how some CARD9-deficient patients can live for
2 or 3 decades before developing any serious fungal infections
while others with identical mutations develop severe fungal
disease early in life. Further study into the pathogenesis of
human CARD9-deficiency will yield exciting new insights into
the mechanisms that protect humans from these devastating
fungal diseases, which should lead to improved therapeutic
strategies for affected patients in the future.
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